A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Condition(s):Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast CancerLast Updated:August 22, 2023Active, not recruiting